TRVI (STOCKS)
Trevi Therapeutics, Inc. Common Stock
$11.004600
-0.245400 (-2.18%)
Prev close: $11.250000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jennifer L. Good
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,416.30M
- Employees
- 33
- P/E (TTM)
- -29.76
- P/B (TTM)
- 7.60
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.08 | $-0.10 | +0.0203 | +20.24% |
|
Jun 2025 (Q2)
|
$-0.09 | $-0.10 | +0.0130 | +12.62% |
|
Mar 2025 (Q1)
|
$-0.09 | $-0.12 | +0.0335 | +27.13% |
|
Dec 2024 (Q4)
|
$-0.11 | $-0.12 | +0.0113 | +9.32% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $5.46M |
| Operating Expenses | $51.35M |
| Research and Development | $36.61M |
| Other Operating Expenses | $14.74M |
| Operating Income/Loss | -$51.35M |
| Income/Loss From Continuing Operations After Tax | -$45.86M |
| Income/Loss From Continuing Operations Before Tax | -$45.89M |
| Income Tax Expense/Benefit | -$32.00K |
| Net Income/Loss | -$45.86M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$45.86M |
| Net Income/Loss Available To Common Stockholders, Basic | -$45.86M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.37 |
| Diluted Earnings Per Share | -$0.37 |
| Basic Average Shares | 132,478,516 |
| Diluted Average Shares | 132,478,516 |
| Assets | $199.36M |
| Current Assets | $198.30M |
| Prepaid Expenses | $1.38M |
| Other Current Assets | $196.92M |
| Noncurrent Assets | $1.06M |
| Fixed Assets | $213.00K |
| Other Non-current Assets | $844.00K |
| Liabilities | $9.57M |
| Current Liabilities | $9.04M |
| Accounts Payable | $2.71M |
| Other Current Liabilities | $6.33M |
| Noncurrent Liabilities | $527.00K |
| Equity | $189.79M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $189.79M |
| Liabilities And Equity | $199.36M |
| Net Cash Flow From Operating Activities | -$44.01M |
| Net Cash Flow From Operating Activities, Continuing | -$44.01M |
| Net Cash Flow From Investing Activities | -$87.37M |
| Net Cash Flow From Investing Activities, Continuing | -$87.37M |
| Net Cash Flow From Financing Activities | $172.20M |
| Net Cash Flow From Financing Activities, Continuing | $172.20M |
| Net Cash Flow | $40.82M |
| Net Cash Flow, Continuing | $40.82M |
| Comprehensive Income/Loss | -$45.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$45.97M |
| Other Comprehensive Income/Loss | -$45.97M |